Fulcrum Therapeutics Inc. (FULC) Misses Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts FULC Hot Sheet
Join SI Premium – FREE
Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.83), $0.17 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.96 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ponce Financial Group, Inc. (PDLB) Tops Q3 EPS by 24c
- CEMEX, S.A.B. de C.V. (CX) Tops Q3 EPS by 4c
- CVR Energy stock climbs ahead of earnings report
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
